KOSDAQBiotech & Pharma377220

From Bio

₩1,201▲ 0.42%2026-11-18 close
Market Cap
₩6.8B
Turnover
₩17,510,560
Volume
10K
Shares out.
5.7M
PER
—
PBR
0.3×
EPS
-₩3,169
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Revenue rebounds but losses persist; balance-sheet strain is the key issue

From Bio's revenue reached KRW 21.7 billion in Q3 2026, up 18.8% year on year, but net losses attributable to controlling shareholders totaled KRW 17.9 billion over the last four quarters and the debt ratio rose to 149.6% in 2025, keeping balance-sheet strain the central variable.

  1. 1

    Q3 2026 revenue was KRW 21.7 billion, up 48.2% from the prior quarter and 18.8% from a year earlier, while the operating loss narrowed year on year to KRW 1.72 billion.

  2. 2

    Annual revenue for 2025 rose 7.4% to KRW 72.2 billion, yet the operating loss stood at KRW 18.6 billion and the net loss attributable to controlling shareholders at KRW 22.5 billion, extending a three-year run of losses that began in 2023.

  3. 3

    The debt ratio climbed from 7.8% in 2022 to 149.6% in 2025, with total liabilities of KRW 39.1 billion exceeding total equity of KRW 26.1 billion at year-end 2025.

  4. 4

    Revenue remains concentrated in a few health-supplement product lines, while the stem-cell-based hair-loss cell therapy candidate targets a clinical trial application in 2027.

  5. 5

    The exchange designated the stock as a short-term investment caution issue on November 17 and 18, 2026 over concentrated sell-side trading in a few accounts, and earlier reports described a management-status designation tied to the market-value threshold.

02

Business structure

From Bio's core business is developing, manufacturing and distributing health functional foods, alongside a cosmetics subsidiary and cell-therapy R&D. Its flagship products are 'Boswellia for Joint Cartilage' and 'Mastic for Stomach Health', and revenue is concentrated in a small number of product lines.

In a 2025 report, health functional foods accounted for more than 80% of revenue, and the two product lines of Boswellia and Mastic made up more than 60% of that segment's sales. The company is shifting away from reliance on home shopping, which fell to 34% of sales in 2024 from 79% in 2019.

It is widening its channels through OEM contract manufacturing, online platforms and overseas sales. Its joint-health solution was recognized with an award at the 2026 National Health Awards.

Overseas, it plans to use a distribution partner's network to expand 35 product lines into North America, Europe and Southeast Asia. Its cosmetics subsidiary has run at a loss since its founding in 2022, according to a 2025 report.

In R&D, the stem-cell-based hair-loss drug candidate has completed nonclinical work, with a target of entering clinical trials in Korea in 2027. In April 2026 the company was selected for a cell-culture materials commercialization program in Gyeongsangbuk-do and began a cell-therapy process standardization project.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩18.3B-₩4.4B−24.3%
2025Q4₩19.5B-₩8B−41.0%
2026Q1₩19.2B-₩3.3B−17.1%
2026Q2₩14.7B-₩600M−3.8%
2026Q3₩21.7B-₩1.7B−7.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩99.3B₩900M₩3.2B0.9%3.7%7.8%
2023₩66.7B-₩15.4B-₩11.1B−23.1%−14.5%29.5%
2024₩67.2B-₩24.3B-₩25.3B−36.1%−50.3%65.3%
2025₩72.2B-₩18.6B-₩22.5B−25.8%−80.1%149.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

Annual revenue fell from KRW 99.3 billion in 2022 to KRW 66.7 billion in 2023, a 32.8% decline, then rose to KRW 67.2 billion in 2024 (up 0.7%) and KRW 72.2 billion in 2025 (up 7.4%), with growth in 2024 and 2025 marking two consecutive years of increases.

Among 2022 to 2025, 2022 was the largest year and 2023 the smallest. A 2026 press report of the company's earlier history cited 2021 revenue of KRW 135.1 billion as the peak.

Operating profit of KRW 897 million in 2022 turned into an operating loss of KRW 15.4 billion in 2023, followed by losses of KRW 24.3 billion in 2024 and KRW 18.6 billion in 2025, which means three consecutive loss years. The operating margin moved from 0.9% in 2022 to -23.1% in 2023, -36.1% in 2024 and -25.8% in 2025.

In 2024 the company wrote off impaired assets in one lump, a big-bath charge that management presented as a step toward a turnaround. Press coverage linked the continuing losses after 2023 to higher advertising and selling, general and administrative expenses.

Net profit attributable to controlling shareholders went from KRW 3.24 billion in 2022 to net losses of KRW 11.1 billion in 2023, KRW 25.3 billion in 2024 and KRW 22.5 billion in 2025. Net income including non-controlling interests was KRW 1.32 billion in 2022 and a net loss of KRW 23.2 billion in 2025.

Total liabilities stood at KRW 39.1 billion against total equity of KRW 26.1 billion at year-end 2025, and the debt ratio rose from 7.8% in 2022 to 149.6% in 2025. Operating cash flow was negative KRW 10.1 billion in 2025.

Quarterly, revenue was KRW 18.3 billion in Q3 2025 with an operating loss of KRW 4.44 billion, then KRW 19.5 billion in Q4 2025 (up 6.6% quarter on quarter) with an operating loss of KRW 8 billion, as losses widened.

Q1 2026 revenue was KRW 19.2 billion (down 1.7%) with an operating loss of KRW 3.28 billion, and Q2 2026 revenue fell to KRW 14.7 billion (down 23.5%) with the smallest operating loss of KRW 553 million.

Q3 2026 revenue rebounded to KRW 21.7 billion (up 18.8% year on year), but the operating loss widened to KRW 1.72 billion and the net loss attributable to controlling shareholders was KRW 2.53 billion.

Over the last four quarters, the net loss attributable to controlling shareholders totaled KRW 17.9 billion, and the company has posted losses in five consecutive quarters. Because quarterly revenue swings are large, the segment mix should be checked in the periodic report.

05

Industry analysis

The domestic health functional food market has lower entry barriers, intensifying competition and exposure to consumer spending, a company official said in a 2025 report. The company is restructuring its product strategy and distribution channels.

A 2025 report noted that its risk diversification lagged competitors with broader product portfolios. Overseas, the company said it began exporting in 2024 but faced difficulty expanding because many countries are unfamiliar with its ingredients.

It was selected as a participant in the 2026 food company overseas certification support program. It is pursuing U.S. FDA New Dietary Ingredient certification for its proprietary Mastic gum complex (FHH-MG), which has been filed in Korea as an individually recognized functional ingredient for hair health.

The biotech segment is still before clinical entry, so its revenue contribution is a medium- to long-term task. The company holds about a 10% stake in a brain-barrier-penetration drug developer.

Within the core supplement business, revenue fell by about half from its 2021 peak in 2023 and 2024 before a modest recovery in 2025.

06

Outlook

The next periodic report is the 2026 annual report, and it will be the first to present fiscal 2026 fourth-quarter results as confirmed figures. Whether the Q3 2026 revenue rebound continues, and which product lines and channels drove the gain, should be checked against segment data in that report.

A report said the company plans to dispose of idle assets to fund growth, pushing global expansion of its health supplements and hair-loss drug development. A related article also said the company is pursuing a sale of idle assets to repay borrowings.

In cell therapy, nonclinical safety testing with repeated-dose toxicity studies has been completed in 2026, additional studies on biodistribution and tumorigenicity are ongoing, and the target is a clinical trial application in 2027.

A key patent of the brain-barrier drug developer in which it holds a stake has been registered, and a report expected business synergies if licensing or listing value rises. For overseas sales, the company plans to expand export volumes depending on how initial orders perform.

The company also said it will invest in expanding its biopharma pipeline on the back of stable business performance. Key checks are the 2026 annual operating margin, the direction of the debt ratio and operating cash flow in the annual report, and whether the 2027 clinical trial application is filed.

07

Valuation

PER
—
PBR
0.3×
ROE
-60.8%
EPS
-₩3,169
BPS
₩3,647
Dividend per share
₩0

The price-to-earnings ratio cannot be calculated because the last four quarters were net losses. The price-to-book ratio sits well below 1x, meaning the share price is below book value per share. This discount to net assets coincides with a period of cumulative losses and a rising debt ratio.

The dividend is effectively negligible, so on yield the stock trails the industry average. Reports said the company was placed under management status because its market value fell below the 20 billion won threshold, and that a court injunction eased delisting concerns.

The caution designations on November 17 and 18, 2026 were based on a three-day sell-side price decline and the share of sell trades by the top ten accounts. Until earnings turn positive, the price-to-earnings comparison is unavailable, so valuation comparisons can only rely on the price-to-book ratio for now.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Revenue rebound and narrower losses

Q3 2026 revenue reached KRW 21.7 billion, up 48.2% from the prior quarter and 18.8% year on year, and the operating loss of KRW 1.72 billion was smaller than a year earlier. Annual revenue for 2025 rose to KRW 72.2 billion, with growth in 2024 and 2025. If the sales recovery continues, the operating margin has room to improve, which is the core bull argument.

External recognition of product strength

The company was named a winner of the 2026 National Health Awards for joint and bone health solutions, recognizing its flagship Boswellia product line. It also received a Ministry of Food and Drug Safety commissioner's commendation at the 2026 K-Health Conference.

The company said human application tests of the ingredient showed improvements in joint pain and mobility indicators.

Overseas channels and pipeline progress

Using a distribution partner's network, the company plans to push 35 product lines into key markets including North America, Europe and Southeast Asia. It is pursuing FDA New Dietary Ingredient certification for its Mastic gum complex. Its cell-therapy candidate remains on a development path that targets a clinical trial application in 2027.

09

Bear factors

Cumulative losses and balance-sheet strain

Net losses attributable to controlling shareholders over the last four quarters totaled KRW 17.9 billion, with losses in five consecutive quarters. With the debt ratio above 100% of equity at year-end 2025, the reasons behind the higher leverage and the repayment plan are the next points to check. Operating cash flow was negative KRW 10.1 billion in 2025.

Product concentration and quarterly revenue swings

A 2025 report cited health functional foods at more than 80% of revenue, with two product lines making up over 60% of that segment's sales. Quarterly revenue fell to KRW 14.7 billion in Q2 2026, down 23.5% from the prior quarter, before rebounding to KRW 21.7 billion in Q3, which shows high volatility.

Listing requirements and trading volatility

Reports said the company received a management-status notice from the exchange after its market value failed to exceed the 20 billion won threshold. It was designated a short-term caution issue for one day on November 18, 2026, with concentrated sell-side trading in a few accounts as the main cause.

10

Risk factors

Financial structure

The debt ratio was 149.6% in 2025, with total liabilities of KRW 39.1 billion above total equity of KRW 26.1 billion. Operating cash flow was negative KRW 10.1 billion in 2025. A plan to sell idle assets to repay borrowings was reported. Asset sales could ease the debt burden, but the operating losses in the core business would remain separately.

Business concentration and regulation

Revenue depends on a few product lines, including Boswellia and Mastic, and a replacement lineup was cited as lacking. The domestic supplement market faces intensifying competition as entry barriers fall.

The cell-therapy timeline, which targets a 2027 clinical trial application, could shift depending on regulatory review and clinical results.

Market trading and governance

The exchange's caution designation is the first step of its market alert system. At the March 31, 2026 general shareholders meeting, an inside director appointment was voted down, with support at 4.6% of total voting shares. The financial statement approval and articles amendment passed.

11

What to watch next

  1. Late March 2027 (annual report filing deadline)

    The 2026 annual report will be the first to present fiscal 2026 fourth-quarter and full-year results as confirmed figures. Key items are the operating margin, the direction of the 149.6% debt ratio and operating cash flow.

  2. 2027 (detailed timing not yet set)

    Whether the hair-loss cell-therapy candidate files a clinical trial application. Filing is required before the program moves into clinical stages.

  3. Timing undetermined (after November 2026)

    The MFDS review outcome for the hair-health individually recognized ingredient and progress on the FDA New Dietary Ingredient certification. These indicate the potential contribution from overseas sales.

  4. Ongoing (per exchange disclosures)

    Whether the company meets the 20 billion won market-value threshold and any new caution or management-status designations. Changes in the share of sell trades by a few accounts are also relevant.

12

Overall view

From Bio's revenue rebounded to KRW 21.7 billion in Q3 2026, but the operating loss of KRW 1.72 billion was larger than in Q2, though narrower than a year earlier.

Based on disclosed figures, 2025 annual revenue rose to KRW 72.2 billion, marking two consecutive years of growth, yet the operating loss of KRW 18.6 billion means three straight loss years.

Net losses attributable to controlling shareholders over the last four quarters totaled KRW 17.9 billion, and the debt ratio rose to 149.6%, increasing balance-sheet pressure.

The business is centered on health functional foods with concentration in a few product lines, and overseas distribution expansion plus MFDS individual recognition and FDA NDI efforts are presented as growth drivers. The cell-therapy candidate targets a 2027 clinical trial application but remains preclinical in stage.

Market events included short-term caution designations on November 17 and 18, 2026 and reports of management-status designation tied to market value.

Revenue recovery and product recognition sit against cumulative losses and balance-sheet strain, and which side dominates should be checked against figures in the 2026 annual report. The next checkpoints are the 2026 annual operating margin, the debt ratio and operating cash flow.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. pharm.edaily.co.kr
  2. dealsite.co.kr
  3. comp.fnguide.com
  4. topdaily.kr
  5. biotimes.co.kr
  6. markets.hankyung.com
  7. innoforest.co.kr
  8. topdaily.kr
  9. m.thinkpool.com
  10. newstap.co.kr
  11. newspim.com
  12. topstarnews.net
  13. m.news.nate.com
  14. kpanews.co.kr
  15. thedailymoney.com
  16. topstarnews.net
  17. m.news.nate.com

Report written 2026-11-19 · Data as of 2026-11-18

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis